BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34183436)

  • 21. Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China.
    Xi S; Sai K; Hu W; Wang F; Chen Y; Wang J; Zeng J; Chen Z
    BMC Cancer; 2019 Jul; 19(1):717. PubMed ID: 31324163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.
    Pajtler KW; Mack SC; Ramaswamy V; Smith CA; Witt H; Smith A; Hansford JR; von Hoff K; Wright KD; Hwang E; Frappaz D; Kanemura Y; Massimino M; Faure-Conter C; Modena P; Tabori U; Warren KE; Holland EC; Ichimura K; Giangaspero F; Castel D; von Deimling A; Kool M; Dirks PB; Grundy RG; Foreman NK; Gajjar A; Korshunov A; Finlay J; Gilbertson RJ; Ellison DW; Aldape KD; Merchant TE; Bouffet E; Pfister SM; Taylor MD
    Acta Neuropathol; 2017 Jan; 133(1):5-12. PubMed ID: 27858204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma.
    Tzaridis T; Milde T; Pajtler KW; Bender S; Jones DT; Müller S; Wittmann A; Schlotter M; Kulozik AE; Lichter P; Peter Collins V; Witt O; Kool M; Korshunov A; Pfister SM; Witt H
    Oncotarget; 2016 Sep; 7(38):61860-61873. PubMed ID: 27556362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
    Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
    PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma.
    Nowak J; Jünger ST; Huflage H; Seidel C; Hohm A; Vandergrift LA; von Hoff K; Rutkowski S; Pietsch T; Warmuth-Metz M
    Clin Neuroradiol; 2019 Dec; 29(4):595-604. PubMed ID: 30027327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MYCN amplification drives an aggressive form of spinal ependymoma.
    Ghasemi DR; Sill M; Okonechnikov K; Korshunov A; Yip S; Schutz PW; Scheie D; Kruse A; Harter PN; Kastelan M; Wagner M; Hartmann C; Benzel J; Maass KK; Khasraw M; Sträter R; Thomas C; Paulus W; Kratz CP; Witt H; Kawauchi D; Herold-Mende C; Sahm F; Brandner S; Kool M; Jones DTW; von Deimling A; Pfister SM; Reuss DE; Pajtler KW
    Acta Neuropathol; 2019 Dec; 138(6):1075-1089. PubMed ID: 31414211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
    Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
    Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Rajeshwari M; Singh M; Suri V; Sarkar C; Sharma MC
    J Neurooncol; 2018 May; 138(1):29-39. PubMed ID: 29354850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of cyclo-oxygenase-2 in ependymal tumors.
    Roma AA; Prayson RA
    Neuropathology; 2006 Oct; 26(5):422-8. PubMed ID: 17080719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ependymoma: Evaluation and Management Updates.
    Rudà R; Bruno F; Pellerino A; Soffietti R
    Curr Oncol Rep; 2022 Aug; 24(8):985-993. PubMed ID: 35384591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Ependymoma in WHO Classification of Tumours 5th Edition].
    Saito R
    No Shinkei Geka; 2023 Sep; 51(5):867-875. PubMed ID: 37743338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ependymoma.
    Reni M; Gatta G; Mazza E; Vecht C
    Crit Rev Oncol Hematol; 2007 Jul; 63(1):81-9. PubMed ID: 17482475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
    Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
    Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.
    Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R
    Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CNS tumors with PLAGL1-fusion: beyond ZFTA and YAP1 in the genetic spectrum of supratentorial ependymomas.
    Tauziède-Espariat A; Nicaise Y; Sievers P; Sahm F; von Deimling A; Guillemot D; Pierron G; Duchesne M; Edjlali M; Dangouloff-Ros V; Boddaert N; Roux A; Dezamis E; Hasty L; Lhermitte B; Hirsch E; Hirsch MPV; Ardellier FD; Karnoub MA; Csanyi M; Maurage CA; Mokhtari K; Bielle F; Rigau V; Roujeau T; Abad M; Klein S; Bernier M; Horodyckid C; Adam C; Brandal P; Niehusmann P; Vannod-Michel Q; Provost C; de Champfleur NM; Nichelli L; Métais A; Mariet C; Chrétien F; Blauwblomme T; Beccaria K; Pallud J; Puget S; Uro-Coste E; Varlet P;
    Acta Neuropathol Commun; 2024 Apr; 12(1):55. PubMed ID: 38581034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ependymomas in Children and Adults.
    Lampros M; Vlachos N; Alexiou GA
    Adv Exp Med Biol; 2023; 1405():99-116. PubMed ID: 37452936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RELA Fusion in Supratentorial Extraventricular Ependymomas: A Morphologic, Immunohistochemical, and Molecular Study of 43 Cases.
    Wang L; Liu L; Li H; Wang P; Hu Z; Wei Y; Zhang M; Wen W; Li Z; Liu L; Zhao L; Lu D; Teng L
    Am J Surg Pathol; 2019 Dec; 43(12):1674-1681. PubMed ID: 31393268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotypic characterization with somatic genome editing and gene transfer reveals the diverse oncogenicity of ependymoma fusion genes.
    Takadera M; Satomi K; Szulzewsky F; Cimino PJ; Holland EC; Yamamoto T; Ichimura K; Ozawa T
    Acta Neuropathol Commun; 2020 Nov; 8(1):203. PubMed ID: 33228790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C11orf95-RELA fusion present in a primary intracranial extra-axial ependymoma: Report of a case with literature review.
    Nambirajan A; Malgulwar PB; Sharma MC; Singh A; Pathak P; Satyarthee GD; Garg A
    Neuropathology; 2016 Oct; 36(5):490-495. PubMed ID: 27121356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Encouraging option of multi-staged gross total resection for a C11orf-RelA fusion-positive supratentorial anaplastic ependymoma.
    Nakamura T; Fukuoka K; Ikeda J; Yoshitomi M; Udaka N; Tanoshima R; Tateishi K; Yamanaka S; Ichimura K; Yamamoto T
    Brain Tumor Pathol; 2017 Oct; 34(4):160-164. PubMed ID: 28831588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.